A
Description
Swedish biotech headquartered in Lund specialised in primary mitochondrial diseases. Its lead candidate KL1333 (NAD⁺ modulator) obtained positive results in the FALCON study. Acquired by Pharming Group (Netherlands) in 2025 for USD 66M.